Form 4: Bristol-Myers Squibb Executive Gregory Scott Meyers Reports Changes in Beneficial Ownership

EVP, Chief Digital & Tech Officer of Bristol-Myers Squibb, Gregory Scott Meyers, reports acquisition and disposal of market share units and performance shares.

Summary

• Gregory Scott Meyers, EVP, Chief Digital & Tech Officer of Bristol-Myers Squibb, filed a Form 4 detailing changes in beneficial ownership.
• The reported transactions involve market share units and performance shares.
• On March 10, 2024, Meyers acquired 19,350 market share units and 29,025 performance shares.
• Additionally, 2,836 and 3,293 market share units were cancelled due to the minimum payout factor not being achieved.
• Following these transactions, Meyers directly owns 5,286 common stock shares, 5,675 market share units expiring in 2026, 9,880 market share units expiring in 2027, 19,350 market share units expiring in 2028 and 29,025 performance shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports transactions and cancellations of equity awards, with no explicit positive or negative commentary. The cancellation of some market share units is a minor negative, but the overall impact is limited.

Positives

• Meyers acquired a significant number of market share units and performance shares, indicating confidence in the company's future performance.

Negatives

• The cancellation of market share units due to not achieving the minimum payout factor suggests that certain performance targets were not met.

Risks

• The value of market share units is dependent on the company's stock performance, and failure to meet performance targets could result in further cancellations or reduced payouts.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the market share units and the distribution of performance shares in 2027 suggest a long-term incentive structure for the executive.

Industry Context

Executive compensation in the pharmaceutical industry often includes equity-based awards like market share units and performance shares to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Equity-based compensation is a common practice among large pharmaceutical companies like Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK).
• The specific terms of these awards, such as vesting schedules and performance metrics, can vary widely depending on the company's specific goals and circumstances.
• The payout factor range of 80% to 225% for the market share units is within a reasonable range compared to similar programs at other companies.

Stakeholder Impact

• The reported transactions could have a minor impact on shareholders, as they reflect changes in the executive's ownership stake in the company.
• The cancellation of market share units could be viewed negatively by employees who were granted those units.

Key Dates